Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis OXNARD, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Oak Therapeutics, a subsidiary of CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, has completed...